((自动化翻译由路透提供，请见免责声明 ))
路透10月14日 - H Lundbeck A/S 与美国长板制药公司（Longboard Pharmaceuticals） 周一表示，两家公司已同意以26亿美元的价格收购长板制药公司，以扩大其治疗神经罕见疾病的产品线。
((自动化翻译由路透提供，请见免责声明 ))
路透10月14日 - H Lundbeck A/S 与美国长板制药公司（Longboard Pharmaceuticals） 周一表示，两家公司已同意以26亿美元的价格收购长板制药公司，以扩大其治疗神经罕见疾病的产品线。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.